The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR
Clinical trial NCT02493582 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02493582
- Sponsor
- The First People's Hospital of Changzhou
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-07-01
- Primary completion
- 2030-07-01
- Enrollment
- 400
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.